David Dai
Stock Analyst at UBS
(2.24)
# 2,833
Out of 5,093 analysts
31
Total ratings
48.15%
Success rate
-1.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $2.52 | +177.78% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $10.67 | +49.95% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $95.85 | +22.07% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $19.51 | +94.77% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $105.09 | +25.61% | 3 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $96.36 | +0.66% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $9.62 | +107.90% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $19.55 | +32.99% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $17.02 | +76.26% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.25 | -11.11% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $12.36 | +94.17% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $36.54 | -34.32% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $15.74 | +338.37% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $34.08 | +46.71% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $41.74 | +43.75% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.54 | +5,121.93% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $88.89 | -55.00% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.39 | +2,777.70% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.90 | +2,531.58% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.70 | +75.08% | 1 | Mar 17, 2020 |
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $2.52
Upside: +177.78%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $10.67
Upside: +49.95%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $95.85
Upside: +22.07%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $19.51
Upside: +94.77%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $105.09
Upside: +25.61%
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $96.36
Upside: +0.66%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $9.62
Upside: +107.90%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $19.55
Upside: +32.99%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $17.02
Upside: +76.26%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.25
Upside: -11.11%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $12.36
Upside: +94.17%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $36.54
Upside: -34.32%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $15.74
Upside: +338.37%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $34.08
Upside: +46.71%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $41.74
Upside: +43.75%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.54
Upside: +5,121.93%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $88.89
Upside: -55.00%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.39
Upside: +2,777.70%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.90
Upside: +2,531.58%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.70
Upside: +75.08%